Literature DB >> 30821421

Wound healing deficits in severe generalized recessive dystrophic epidermolysis bullosa along anticancer treatment with cetuximab.

Katharina Medek1, Peter Koelblinger1, Josef Koller1, Anja Diem2, Katharina Ude-Schoder2, Johann W Bauer1, Martin Laimer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30821421     DOI： 10.1111/ddg.13802

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN： 1610-0379            Impact factor:   5.584


× No keyword cloud information.
  5 in total

Review 1.  Integrated Management Strategies for Epidermolysis Bullosa: Current Insights.

Authors:  Haseena Sait; Somya Srivastava; Deepti Saxena
Journal:  Int J Gen Med       Date:  2022-05-24

Review 2.  Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.

Authors:  Angelo Giuseppe Condorelli; Elena Dellambra; Elena Logli; Giovanna Zambruno; Daniele Castiglia
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

3.  Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.

Authors:  Susan J Robertson; Elizabeth Orrin; Manpreet K Lakhan; Gavin O'Sullivan; Jessie Felton; Alistair Robson; Danielle T Greenblatt; Catina Bernardis; John A McGrath; Anna E Martinez; Jemima E Mellerio
Journal:  Acta Derm Venereol       Date:  2021-08-24       Impact factor: 3.875

4.  Transcriptome-Guided Drug Repurposing for Aggressive SCCs.

Authors:  Roland Zauner; Monika Wimmer; Sonja Dorfer; Michael Ablinger; Ulrich Koller; Josefina Piñón Hofbauer; Christina Guttmann-Gruber; Johann W Bauer; Verena Wally
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

5.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.